This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Expanded Access for Idelalisib in Combination With...
Clinical trial

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Read time: 1 mins
Last updated:9th May 2014

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

Category Value
Study start date 2014-05-09

View full details